Track Healthy Aging Across Species: What the Dog Aging Project Can Teach Us

A dog’s lifespan is shorter than a human’s, but many of the challenges of aging look familiar: declining mobility, cognitive changes and chronic disease. The Dog Aging Project follows pet dogs over time to ask which aspects of aging are shared across mammals, and which depend on genes, environment or species.

A new approximately $29 million, five-year NIH funding commitment will help researchers move beyond recording what happens as dogs age toward investigating why their health trajectories differ. Here is how to interpret that work, and what to do while the evidence develops.

The Science Behind It

Dogs occupy a useful middle ground in aging research. Unlike laboratory animals living in tightly controlled conditions, companion dogs share many human environments. They breathe indoor and outdoor air, drink local water and experience varied diets and activity patterns. They also develop some diseases and functional changes associated with aging in people. Because dogs generally live shorter lives, researchers can observe a substantial portion of their life course over a comparatively short period.

That combination creates an opportunity to test whether patterns seen in one mammal appear in another. For example, chronic low-grade inflammation is associated with aging and age-related disease in humans and other animals. A 2023 review in Signal Transduction and Targeted Therapy describes how aging cells can release inflammatory signals that affect surrounding tissue. If researchers observe related biological patterns alongside health changes in dogs, those findings could strengthen the case that some aging processes are shared across species.

Shared biology does not mean identical biology. A 2023 human study by Oh and colleagues found that protein patterns in blood could help estimate differences in the aging of individual organs and track health and disease (Nature). That study does not establish an equivalent test for dogs. It illustrates a broader question relevant to both species: could biological measurements reveal differences in aging before major disease becomes apparent?

The protocol below is a way to follow that question without treating early animal findings as ready-made human interventions.

The Protocol

Phase 1: Establish what the funding will enable

Start by separating the project’s existing observations from the questions the new funding aims to answer.

• Know the cohort: Nearly 55,000 companion dogs have enrolled since 2018, according to the funding report. Owners have contributed information about factors such as diet, activity and health over time. Enrollment does not mean every dog has a complete lifetime record or participates in every measurement.
• Follow the money: The NIH commitment is approximately $29 million over five years, with $6.1 million in the first year supporting a team led by Tufts University, with Texas A&M University also involved. The next phase will continue longitudinal follow-up while adding more detailed biological and environmental information.
• Watch for direct exposure measurements: Researchers plan to analyze drinking water, use chemical-absorbing tags to assess airborne pollutants and fit activity trackers to a subset of dogs. These measures can complement owner reports, which may be incomplete or affected by recall.
• Expect a closer look at cognition and resilience: Owners will continue health reporting and home-based cognitive assessments. Researchers also plan to study dogs that live exceptionally long lives for their size, using health records and genetic samples to investigate factors associated with resilience.

Caveat: These are planned research activities, not proof that a particular pollutant, diet or gene causes faster aging. Results and analyses will determine what the data can support.

Phase 2: Evaluate whether a canine finding translates to humans

When a result appears, use the same four questions before changing your own health routine or your dog’s care.

• What was measured? Distinguish an owner-reported habit from a direct measurement, and a biological marker from a meaningful outcome such as disease, cognitive function or lifespan. A marker can offer a useful clue without proving that an animal is aging faster or slower.
• Was the study observational or experimental? Much of the project follows dogs in their usual lives. That can identify associations, but it cannot by itself establish cause and effect. Dogs eating a particular diet, for example, may also differ in body size, health history or veterinary care.
• Were major differences accounted for? Breed and body size matter when comparing canine lifespans. An exceptionally old dog should be assessed against a meaningful comparison group, not simply against all dogs combined. Researchers also need to consider other factors that could help explain an association.
• Has the finding been tested beyond dogs? A similar pathway or risk pattern in dogs and humans is a reason for further investigation. It is not enough to establish that an intervention works in both. Look for independent replication and, when appropriate, carefully designed human studies before drawing conclusions about human health.

This cross-species process runs in both directions. Human research can help researchers choose questions to examine in dogs; canine findings can generate hypotheses for human studies. Translation requires testing, not just a plausible biological resemblance.

Phase 3: Track health without waiting for a longevity shortcut

The project’s approach is useful now as a reminder to observe changes over time, even though it has not established a new prevention regimen for humans or dogs.

• Keep a simple baseline: For your own health, record relevant measures already recommended by your clinician and note meaningful changes in function, such as exercise tolerance or memory concerns. Bring persistent changes to an appointment rather than trying to diagnose them from a tracker.
• Observe your dog’s normal patterns: Notice changes in appetite, mobility, sleep, activity or behavior and discuss persistent or concerning changes with a veterinarian. Age alone should not be used to dismiss a new symptom.
• Make prevention individual: Ask your veterinarian about an appropriate weight-management, activity and screening plan for your dog’s age, size and health. For yourself, use routine preventive care and discuss personal risks with a qualified clinician.
• Review new claims cautiously: If a product is marketed as targeting an aging pathway, ask whether it improved meaningful outcomes in the relevant species, not merely a laboratory marker. Do not give a human longevity treatment to a pet, or adopt a canine intervention yourself, based on a shared mechanism alone.

Key Takeaways

• The funding expands a long-term study: Approximately $29 million over five years will support continued follow-up and more detailed investigation of biological and environmental factors in aging dogs.
• Dogs offer a valuable comparison, not a human substitute: Shared environments and some shared diseases help researchers test hypotheses across mammals, but species differences still matter.
• Use the findings as questions, not prescriptions: Track meaningful health changes, maintain individualized preventive care and wait for stronger evidence before treating a canine association as a human longevity intervention.